+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy

Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy

Clinica E Investigacion en Arteriosclerosis 28(2): 87-93

LDLc levels are associated with increase of cardiovascular risk, and statins are currently used for their control. Nevertheless, a despite of LDLc levels at goal, a residual risk is persistent, commonly associated with persistent lipids modifications (high triglycerides and low HDLc). So, it is necessary to evaluate triglycerides and HDL to assessment cardiovascular risk. Clinical data are consistent with efficacy and safety of combination therapy with statin and other lipid lowering drugs, for instance fenofibrate. Patients with hipertriglyceridemia and low HDLc are the group with most potential improve. In that patients with atherogenic dyslipidemia, the target for therapeutic objectives related with non-HDL-cholesterol is a priority, because non-HDL-cholesterol is considered as a more accuracy measure to assessment cardiovascular risk.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057493251

Download citation: RISBibTeXText

PMID: 26811267

DOI: 10.1016/j.arteri.2015.12.001

Related references

What is the contribution of the review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidemia? Report on consensus of experts in the importance of the combined therapy by fenofibrate with statin. Vnitrni Lekarstvi 61(11): 971-975, 2015

A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atherosclerosis. Supplements 19: 1-12, 2016

Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy. International Journal of Cardiology 248: 355-360, 2017

Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia. Journal of Lipid Research 56(12): 2381-2392, 2015

Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). American Journal of Cardiology 101(4): 486-489, 2008

Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clinical Cardiology 29(6): 268-273, 2006

Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia. Cardiovascular Therapeutics 32(4): 139-146, 2014

Combined therapy with omega-3 fatty acids and niacin in atherogenic dyslipidemia. FASEB Journal 15(4): A639, 2001

Pilot study of combined therapy with ω-3 fatty acids and niacin in atherogenic dyslipidemia. Journal of Clinical Lipidology 1(3): 211-217, 2007

Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy. Endocrinology and Metabolism Clinics of North America 33(3): 525, 2004

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. American Journal of Cardiology 81(4a): 60b-65b,. 26, 1998

Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?. Current Pharmaceutical Design 19(21): 3858-3868, 2013

Pharmacologic modulation of the atherogenic LDL profile in dyslipidemia. Woodford, F P, Davignon, J, Sniderman, A International Congress Series; Atherosclerosis X 83-87, 1995

Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. American Journal of Cardiology 102(8): 1040-1045, 2008

Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke 45(5): 1429-1436, 2014